First Tracks Biotherapeutics, Inc. Ordinary Shares TRAX
Analyst Ratings
- Consensus
- Buy — 11 Buy · 0 Hold · 0 Sell (11 analysts)
- Avg. Price Target
- $66.27 (+94.2% upside)
Key Stats
- Today's Range
- $30.88 – $34.32
- 50-Day Range
- $30.11 – $49.91
- 52-Week Range
- $14.72 – $49.91
- Volume
- 982K shs
- Average Volume
- 1.00 million shs
- Market Cap
- $1.13 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 11.28%
- Days to Cover
- 7.50
About First Tracks Biotherapeutics, Inc. Ordinary Shares
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Related Stocks
Compare head-to-head: TRAX vs LLY·TRAX vs JNJ·TRAX vs ABBV·TRAX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.